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CRITICAL PERSPECTIVES
International law, public health, and the meanings of
pharmaceuticalization
Emilie Cloatrea∗ and Martyn Pickersgillb
aKent Law School, University of Kent, Canterbury, UK; bCentre for Population Health
Sciences, University of Edinburgh, Edinburgh, UK
(Received 28 March 2014; ﬁnal version received 31 July 2014)
Recent social science scholarship has employed the term “pharmaceuticalization”
in analyses of the production, circulation and use of drugs. In this paper, we seek
to open up further discussion of the scope, limits and potential of this as an
analytical device through consideration of the role of law and legal processes
in directing pharmaceutical ﬂows. To do so, we synthesize a range of
empirical and conceptual work concerned with the relationships between
access to medicines and intellectual property law. This paper suggests that
alongside documenting the expansion or reduction in demand for particular
drugs, analysts of pharmaceuticalization attend to the ways in which socio-
legal developments change (or not) the identities of drugs, and the means
through which they circulate and come to be used by states and citizens. Such
scholarship has the potential to more precisely locate the biopolitical
processes that shape international agendas and targets, form markets, and
produce health.
Keywords: access to medicines; drugs; patents; pharmaceuticalization; TRIPS
Introduction
We live, it seems, in an age of drugs. In spite of concerns that there is a crisis of
innovation with the pharmaceutical industry (Hopkins et al. 2007), it is neverthe-
less clear that the use of chemical compounds to treat disease, enhance health,
and practice recreation is increasing internationally: drugs “seem to be only
growing in importance” (Sismondo 2004, 157). Indeed, as historian Greene
notes, the expansion of access to pharmaceuticals “has become one of the most
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visible aspects of twenty-ﬁrst century global health practices” (2011, 10). Some
social scientists have characterized this emphasis on drugs within medicine,
health and everyday life as a process of “pharmaceuticalization” (e.g. Abraham
2010; Biehl 2007; Fox and Ward 2008; Williams, Martin, and Gabe 2011).
In this analytic essay, we reﬂect on how pharmaceuticalization relates to the issue
of access to medicines in “least developed countries.” We focus in particular on the
nexus between access and intellectual property law, interweaving our own empiri-
cal ﬁndings with wider writings in this broad area of research (from science and
technology studies (STS), sociology, anthropology, bioethics, and legal studies).
In presenting such a synthesis, our paper represents neither a traditional literature
review nor a pure research report. Instead, our contribution stands as an analytic
essay that brings together various conceptual points and empirical ﬁndings into
concert in order to prompt new conversations in STS and cognate disciplines
about pharmaceuticalization (speaking to a broader project that we call the
“social studies of law” (Cloatre and Pickersgill, forthcoming)).
Speciﬁcally, we want to urge for more social scientiﬁc attention to the role of
“the legal” in constituting the social lives of drugs, and to assert that the place,
role and impact of law and legal processes in directing pharmaceutical ﬂows are
complex, contingent, and multidirectional. Of course, as we will see later in the
paper, these issues have already been a matter of concern for some scholars
(perhaps most notably, for the sociologist John Abraham, who has produced a
voluminous body of work on pharmaceutical regulation). Yet, international law
and more socio-legal approaches to comprehending this are not the core features
of STS and other writings on the place, role and impact of drugs in and on
society.
This paper draws on examples of recent instances in which the complexity of the
links between access and intellectual property law has been demonstrated. We
attend especially to “TRIPS,” i.e. the World Trade Organization’s Agreement on
Trade-Related Aspects of Intellectual Property Rights. This is a controversial
piece of legislation that is regarded as “plainly unjust” by many (Pogge 2008,
76), and is commonly associated with changing patterns of pharmaceutical con-
sumption. Explorations of TRIPS are salient for broader considerations of pharma-
ceuticalization, especially if we are to be concerned with contexts outside of “the
West.”1 Throughout, we understand law as a kind of “technology” in and of
itself – a means by which material and semiotic change is leveraged (Lessig
1999; Pickersgill 2013; Yeung and Dixon-Woods 2010). What law “does” to
drug markets and use is our key concern.
In what follows, we critically explore existing work on drugs and society, before
interrogating and historicizing the (primarily legally oriented) debates around
TRIPS and related access to medicines campaigns. We conclude with reﬂections
on the import of this analysis for wider debates around pharmaceuticalization,
and the use of interrogating the development and implementation of legal technol-
ogies for understanding this set of processes.
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Pharmaceuticalization: drugs and society
The concept of pharmaceuticalization has its origins in empirical social scientiﬁc
analyses of the production, circulation and use of drugs (Petryna and Kleinman
2006), “objects whose social relations are more hidden” (Pollock 2008, 534)
than other frequently studied actants within assemblages of health (such as phys-
icians and biomedical technologies).2 More recently, medical sociologists Simon
Williams, Paul Martin and Jonathan Gabe have deﬁned pharmaceuticalization as
“the translation or transformation of human conditions, capabilities and capacities
into opportunities for pharmaceutical intervention” (Williams, Martin, and Gabe
2011, 711). Similarly, John Abraham refers to it as “the process by which social,
behavioral or bodily conditions are treated, or deemed to be in need of treat-
ment/intervention, with pharmaceuticals by doctors, patients, or both” (Abraham
2010, 290).
Following the seminal work of Conrad (2005), Abraham (2010) has argued that
medicalization is a key mechanism by which pharmaceuticalization occurs, at the
same time as deregulatory state policies and increased consumerism promote drug
development and consumption. Particularly important examples of this can be
found in the simultaneous expansion in the use of drugs aimed at treating mental
ill-health, and the range of psychiatric disorders themselves that are recognized
by different medical institutions (Lane 2009; Lee 1999; Scott 2006). The pharma-
ceutical industry, notes psychiatrist and historian David Healy, “now sell diseases
rather than just drugs” (Healy 2006, 82).3 Recent scholarship has also brought to
light the great extent to which psychopharmaceutical use may be operationalized
as a form of “enhancement,” rather than “therapy” (Coveney, Williams, and
Gabe 2011; Fox and Ward 2008; Hogle 2005; Martin et al. 2011; Williams,
Martin, and Gabe 2011).
Research itself can be a powerful means through which health systems can
become pharmaceuticalized (Dumit 2012), and clinical trials can act as a means
of product promotion for drug companies (Petryna 2009). Indeed, it may be market-
ing departments that help to determine what trials are undertaken, and how the
results will be disseminated (Healy 2006, 73). As Petryna (2009) shows, trials in
low-income countries can act as platforms for the introduction of new drugs –
which may sometimes be highly expensive, for pathological indicators (such as
cholesterol) rather than “diseases” per se, and little more efﬁcacious than existing
treatments (see also Lakoff 2005; Petty and Heimer 2011). In such instances, it
might be patients themselves who campaign for greater access to these pharma-
ceutical solutions to what may be symptoms of more pervasive problems in
public health infrastructure.
Citizens, then, may actively ally themselves with what Adele Clarke and col-
leagues might refer to as the “Biomedical TechnoService Complex Inc.” (Clarke
et al. 2010), and have consequently been active agents in pharmaceuticalization
of their societies. For instance, as documented by Biehl (2007), in Brazil a
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policy of universal access to antiretroviral drugs (ARVs) was made possible
through a novel alignment of activists, public sector institutions and the pharma-
ceutical industry itself. This had the effect of diverting public health priorities
away from prevention, and toward the wide distribution of drugs. Medicalization,
then, is not, a priori, necessary to support pharmaceuticalization. Instead, industry
campaigns may work to enjoin consumers to recognize existing medical categories
as necessarily needing more and better drugs to improve their condition (Abraham
2010). The alignment of patient and industry interests may be achieved in ways that
have led to deep criticism of the industry; for instance, in regard to their direct spon-
sorship (and even creation) of patient/consumer groups (Lane 2009).
Macro-social trends in the production, circulation and consumption of drugs are
powerfully governed by collective and individual responses to and conceptualiz-
ations of health, illness and the body. Pharmaceuticalization is intrinsically
social: it is shaped by social and economic imperatives and structured by societal
norms. These are in turn (co-)produced through a range of regulatory processes,
including law per se. Accordingly, the role of governance and law in the mechanics
of (de)pharmaceuticalization is gradually coming into sharper focus within social
scientiﬁc and humanities scholarship (Carpenter and Tobbell 2011; Ecks and
Basu 2009; Hayden 2007, 2011). Ideologies of deregulation have expanded the
consumption of pharmaceuticals (Abraham 2010, 616);4 this is especially
evident where patients and industry have collaborated through campaigns and liti-
gation to improve access to drugs (Abraham 2010, 611; see also Biehl 2006, 2007).
Indeed, regulators themselves have also played a role in increasing the number of
drugs available on the market: in the USA, for instance, more lenient regulatory
standards for cancer drugs have increased the focus of industry in this area
(Davis and Abraham 2011). Contract research organizations (CROs) continue to
examine the regulatory environment of prospective countries that might act as
trial sites, assessing potential approval times for trials and whether it makes
sense to market the drug there (Petryna 2009, 16). In what follows, we consider
further some of the legislative aspects of drugs, paying particular attention to intel-
lectual property.
Making law, circulating drugs
When examining the legal context of drug use, it is difﬁcult to miss the importance
of patents. Granting a 20-year monopoly on speciﬁc medicines, patents deﬁne own-
ership and entitlements over a drug and uniquely position it within international
markets. The patented drug becomes the ﬁrst “face” that patients will associate
with a speciﬁc pharmaceutical, often resulting in long-term ﬁdelity. Consequently,
patents shape the social nature of medicines, making them one of the most essential
aspects of the regulation of pharmaceuticals.
The issue of how patents should be protected has always created very intense
debates. Whilst they are formally a particular kind of ownership, and have the
New Genetics and Society 437
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 07
:00
 05
 N
ov
em
be
r 2
01
4 
effect of creating a quasi-monopoly for a set period of time over pharmaceuticals,
patents are also much more complex socio-legal tools that have the potential to
embed elements of history, power relation, and conceptions of (in)justice. In
addition, their deployment in practice follows material and social paths that
make them unpredictable and messy actants (Cloatre 2013; Ecks and Basu
2009). The processes of social (dis)ordering that are generated by patents are there-
fore multiple; in their effects, they are sometimes subtle, sometimes profound.
The relationship between intellectual property and access to health has for a long
time been studied through the lens of TRIPS and its impact. Patent law has tra-
ditionally been designed almost exclusively at the national level, but in 1995,
TRIPS created new international standards in the ﬁeld of intellectual property,
and sought to introduce new minimum legal standards for the (strong) protection
of IP into international trade. This ensured harmonization between WTO
members with the aim of preventing infringements and granting the authority to
exact injunctions and/or penalties where this occurs. TRIPS is associated with pro-
viding a strong legal basis for the protection of pharmaceutical patents granted in
one jurisdiction in domains that had not previously respected these.
TRIPS has thus been considered to be particularly signiﬁcant to countries that
previously had no (or a very light) system of protection for patents on pharmaceu-
ticals. In some cases, this was out of policy choice – in India, for example (Hen-
derson 1997; Keayla 1999), where patent protection was offered for pharmaceutical
processes but not products. This allowed for the reverse engineering of branded
pharmaceuticals and the rise of a generics industry. Connecting capitalism to
care, the Euro–American pharmaceutical industry argued that if their proﬁts
were harmed through generics, then R&D would decrease.5 Accordingly, strong
patent protection was demanded, with concerns about infringement commonly
articulated in public health terms (e.g. Peretz 1983, 262). In effect, the proliferation
of generics was framed as having the potential to stall some of the machinery
driving forward pharmaceuticalization (i.e. the innovation of new drugs) that
were understood as being very good for global health (see also Ecks 2008, 165).
Following TRIPS, Euro–American industry concerns were translated into law.
Soon after its signing, however, TRIPS was attacked for creating a danger for
public health in developing countries. While generics had been widely portrayed
as a threat to innovation (and, hence, ultimately, the pace and practice of pharma-
ceuticalization), the global expansion of drug patents that TRIPS generated became
criticized for restricting access to medicines for the poorest (Picciotto 2002; Pogge
2008; Sell 2003). Critics commonly ﬁgure TRIPS as encouraging further pharma-
ceuticalization in high-income countries, while halting it in poorer nations.
Central to these discourses are the notions of “essential medicine,” speciﬁed by
the WHO as the “minimum medicine needs for a basic health-care system, listing
the most efﬁcacious, safe and cost-effective medicines for priority conditions”
(WHO 2011, 3). Such conditions are included “on the basis of current and esti-
mated future public health relevance and potential for safe and cost-effective
438 E. Cloatre and M. Pickersgill
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treatment” (WHO 2011, 3). Yet, distinguishing “essential” medicines remains pro-
blematic (Greene 2011, 10). Some suggest that since many essential medicines are
off-patent, TRIPS will not impact negatively on health (Attaran 2004; Noehrenberg
2006). However, critics argue that it is precisely because drugs are off-patent (and
hence cheaper) that they appear on the list (‘t Hoen 2010). Accordingly, we can
begin to see the important role that patents can play in constituting the identity
of drugs: in this case, whether or not medicines are “essential” (Cloatre 2008b).
TRIPS has thus activated a range of social, legal and health developments. Key
questions pertaining to TRIPS include the following: with the extension of pharma-
ceutical patents to new spaces (increasing the monopoly of Big Pharma and
decreasingly the market for generics), how would the price of drugs be affected?
More pertinently, would this reduce access to medication for the poor and thus
further increase global health inequalities? TRIPS therefore represents an important
example of the ways in which legal tools can shape pharmaceutical consumption –
and of how this is itself enrolled as a criterion for assessing both the need for and
the effectiveness of law. The aforementioned account is also suggestive of the
extent to which legal innovation animates new discussions about the management
of health (e.g. the dialectic between concerns that pharmaceuticals are too seldom
available, and worries that they are too often prioritized).6
Translating global law
International law, as is the case for legal technologies more generally, can only
acquire agency if enacted through local practice. Recent investigations into the
social action that surrounds pharmaceutical patents and TRIPS in less-explored jur-
isdictions have demonstrated that the immediate authority, remit and relevance of
international law are complex and contingent (Cloatre 2008a, 2008b, 2013).
Whether countries were expected to create entirely new IP systems as a result of
TRIPS (as is the case for many least developed countries, such as Djibouti,
Cloatre 2008a, 2008b, 2013), or “simply” had to amend their national laws (for
example Ghana; Cloatre 2013), the process of turning TRIPS into national law,
and national law into new practices, is slow, complex and uncertain. In many con-
texts, the lack of local expertise, interest, or mobilization means that this is likely to
take many years before any change in practices is noted. This needs to be accounted
for in assessments of the role of law in directing pharmaceutical ﬂows.
As we have discussed at length elsewhere (Cloatre 2013), there is a discrepancy
between the imagined version of legal systems in which TRIPS is expected to be
deployed, and the day-to-day micro-practices of law, health, and pharmaceutical
markets in particular countries. In effect, the sociotechnical imaginaries (Flear
and Pﬁster, forthcoming; Jasanoff and Kim 2009; Pickersgill 2011) projected by
lawmakers may be distant from life as lived. More broadly, the enactment of law
cannot be assumed through the existence of a small circle of intellectual property
specialists; rather, the praxis of health professionals, public health experts, and
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perhaps also patients needs to be reshaped. Chains of association need to be forged,
and in many places, in Africa and elsewhere, this is especially challenging given
that pre-existing bridges between this diverse range of actors are rare. This compli-
cates assumptions about the possibility of straightforwardly translating inter-
national law into speciﬁc nation states or localities – and, hence, challenges the
idea that “global governance” really is global in nature and effects. Accordingly,
the effect of TRIPS in these locations may be less direct or visible than reinforcing
patents, and therefore (de)pharmaceuticalizing markets.
Our overall point is that a working pharmaceutical patent system is a complex
sociotechnical network organized in diverse ways in different jurisdictions that
depends on the ability of the system of import and marketing of medicines to
respond to the requirements of patent law. The licensing of drugs, for instance,
may be made to include a check on the patent status of particular drugs; if so, the
post-market surveillance system will need to respond to this requirement: custom
ofﬁcers need to be aware of this particular set of regulatory limits on which speciﬁc
versions of drugs may be allowed to enter the country, they need to have the material
artifacts necessary for reporting, they need to recognize this as a feature of their
everyday work that must not be ignored, there must be systems in place to ensure
their compliance, and so on. Indeed, the deployment of such systems in practice
may be problematic even in countries that have granted patents on pharmaceuticals
formany years (Cloatre 2013), and is evenmore complex to create in the ﬁrst place in
states that have no pre-existing institutions. Consequently, inmany places, law exists
on paper, but not in practice. Without resources or expertise, and if it is seen to
respond to the needs of others, elsewhere, rather than those experienced within the
jurisdiction, legal tools are unlikely to be enacted. In what follows, we move from
an examination of the kinds of debates TRIPS has stimulated to an exploration of
speciﬁc practices of distribution and access to drugs, and the multidirectional
effects that patents seem to have on the daily practices of health care.
The shaping of drug markets7
In this section, we reﬂect further on the indirect role that patents can play in
locations where the deployment of law is less visible or straightforward than the
creators of TRIPS may have expected, examining how and why generic medicines
can fail to become inﬂuential, even when patent law was formally implemented.
The difﬁculties for generics to become central to public health in much of
Africa, and in many least developed countries, are widespread (WHO and Direction
de la Pharmacie, du Me´dicament et des Laboratoires 2004). Research we carried
out in Ghana indicates, for example, that the efforts of the government to increase
the use of generics in public hospitals are being held back by a routinized reliance
on branded medicines (Cloatre 2013; see also Ghana Ministry of Health 2008). In
particular, the entanglement of brands, as opposed to substances, in the practices of
patients and health professionals, means that patented drugs are likely to occupy a
440 E. Cloatre and M. Pickersgill
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strengthened position long after the rights granted by the patent have expired. The
embedding of brands within doctors’ prescriptions (Ecks and Basu 2009), them-
selves linked to factors ranging from ease and habit to proactive targeting by the
pharmaceutical industry, is determinant in establishing which drugs get to patients.
Furthermore, patents play a part in extending legal tools, which may, at times, mean
that drugs will simply stop getting to patients. In some places, this will translate into
a monopoly. In others, it means that the supply of cheap medicines to patients may
be hindered by the fact that the market in cheap, generic medicines remains con-
strained and limited.
The example of Djibouti – a small country in the northeast of Africa that we
have explored in more detail elsewhere (Cloatre 2008a, 2013) – is a good illus-
tration of some of these complications, and it is worth discussing in a little more
detail since it reveals the roles patents may play even in systems where they
have, formally, no existence. Until recently, there was no patent law in Djibouti.
In practical terms, this meant that any medicine could legally come into the
country: the identities of drugs – whether there were branded, generic, or
patented – were not simply uninteresting to, but in effect unrecognized by regula-
tors who lacked any kind of legal framework through which to make visible the
differences that TRIPS codiﬁed as so signiﬁcant. Nonetheless, in spite of this a
very narrow range of drugs was imported. In the private sector, which forms the
biggest part of the pharmaceutical market, generic drugs were almost systemati-
cally excluded in practice. The absence of ofﬁcial law on pharmaceutical patents
did not mean, therefore, that the drug market in Djibouti was unregulated; as
recent approaches to regulation theories have highlighted, regulatory processes
are often deployed aside from or instead of formal state regulations (Black 2002;
Cloatre and Dingwall 2013). In this case, other agendas governed the importation
of pharmaceuticals, in different and unexpected ways, revealing not only aspects of
the direct inﬂuence of the global pharmaceutical industry that has been well docu-
mented, but also the internalizing and perpetuating of speciﬁc practices by local
importers and health professionals. Harper, Rawal, and Subedi (2011) have demon-
strated similarly complex links between the “unregulated” market of Nepal and the
repeated dominance of branded medicines within it, although the processes that
create this situation are slightly different in their example – and indeed, one of
the features of these links between market and regulatory systems is their
context-speciﬁc nature.
This suggests that the concerns of TRIPS critics and access to medicines cam-
paigners that the agreement might further limit the opportunities of individuals
in low-income countries to consume drugs do not hold everywhere – and in
some contexts limitations are in place independently of the presence or absence
of speciﬁc laws. Furthermore, concerns about TRIPS may perhaps need readjusting
in other places. This is not to say that TRIPS, or that patents, are not highly proble-
matic: instead, it suggests that the “problem” of patents may run deeper and be
more subtle than one of “increased law/decreased access.”
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Access to medicines campaigns and pharmaceutical ﬂows
The role of global regulation in shaping access to drugs, and processes of
(de)pharmaceuticalization is also rendered more complex by the fact that the
effects of any law are not only the creation of new rights, and new rules, but
also wider social transformation (including mobilization and resistance). In the
case of TRIPS, the processes that these new increased IP demands have generated
have also provided international campaigns around access to medicines (such as
those of Medecins Sans Frontieres) with signiﬁcant impetus. Indeed, one of the
effects of TRIPS has been to galvanize an opposition that has been effectively
working at addressing some of the very issues that countries such as Djibouti
and Ghana have faced.
In these resistant narratives, the processes of depharmaceuticalization that might
be triggered or aggravated by TRIPS need to be addressed by increasing the ﬂow of
cheap medicines that are affordable for the poor. In turn, these campaigns them-
selves have attracted critique; for instance, some have questioned whether govern-
ments and NGOs today are too focused on the treatment of AIDS, and as such
ignoring other diseases to the detriment of entire populations (Shiffman 2008).
The wide range of programs created cannot be reviewed fully here, but a few
points can be made to illustrate, again, the multidirectionality of the links
between law and (de)pharmaceuticalization.
Again, the case of Djibouti is particularly telling, in that one of the biggest inter-
national programs set up in its health sector since TRIPS has been aimed at
encouraging the import and use of generic medicines. This was targeted, mostly,
through the development of dedicated “pharmacies communautaires” around the
country, in which some cheap generics could be sold by bypassing the dominant
import system described earlier. This means that in some locations in Djibouti,
access to drugs may have paradoxically increased as a result of the mobilization
generated by TRIPS.
The situation in Djibouti is illustrative rather than unique. In the past 15–20
years, campaigns for access to medicines have successfully exposed and trans-
formed some of the injustices of the global pharmaceutical market. TRIPS can
thus be understood to have played a signiﬁcant, unanticipated and unwilling role
in activating this mobilization (Sell 2003). Conceptually, this raises difﬁcult ques-
tions in relation to how the role of the law may be approached. In particular, it
suggests that linear understandings of legal processes, or indeed of processes of
increased or decreased access to pharmaceuticals, might not account for the multi-
faceted ways in which global regulation affects local markets – or indeed, how we
may wish to conceptualize the boundaries of what these legal regulations are and do
(for example, the extent that resistance can be understood as “effects”). In regard to
understandings of pharmaceuticalization, we can see that the movements of par-
ticular drugs are shaped by the ambiguous effects of speciﬁc “global” and
“local” events.
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In addition, the transformations that followed the global mobilization against IP
and for access are played out in ways that are not only about processes of (de)phar-
maceuticalization, but also about changes in the type of pharmaceuticals that are the
focus of health priorities. One effect of the debates on IP, for example, has been to
increase awareness of the difﬁculty in getting access to patented (“modern”) medi-
cines. In particular, international attention has most heavily focused, in response to
TRIPS, on funding and sustaining access to the few drugs on the WHO’s essential
medicines list which are under patent (and hence expensive) – primarily, ARVs for
HIV/AIDS (MSF/WHO/UNAIDS Secretariat 2003). As the cost of ARVs and the
impact that patenting rules had on them became more publicized, extensive cam-
paigning focusing on access emerged globally, and funding for these has steadily
increased since the mid-1990s. As a result, access programs for ARVs have been
implemented in many countries. The debate has subsequently broadened to ques-
tion the prioritization of “modern drugs” over “basic medication.” Processes of
shifting attention to drugs in general also involve decisions over which drugs
should be prioritized. Such discourses underscore how “AIDS medicine is socially
as well as pharmacologically active in that it occasions reﬂections on social
relations and distinctions” (Reynolds Whyte et al. 2006, 241).
Alongside ARVs, particular attention has been paid to TB and malaria, two dis-
eases for which the issue of innovation and access to new medicines is acute.
Again, one question that has arisen in response to the heed paid to TB and
malaria is the extent to which this has meant that attention has shifted from
issues of generalized access to pharmaceuticals as a whole, to issues of access to
certain type of medicines. Moreover, the progressive reshaping of drug markets
through access programs has raised new questions about dependency and (de)loca-
tion of the making of drugs that, once more, complicate analytic comprehension of
the social, legal and political dimensions of global ﬂows of medicines. For
example, the emergence of new regulation for the making of medicines for globally
funded programs, and in particular the WHO pre-qualiﬁcation program, is increas-
ingly constraining and delimiting which drugs can or cannot be enrolled into local
pharmaceutical markets. Access to particular medicines therefore becomes con-
ditioned on the enrollment of particular places of production (not only of medi-
cines, but also of regulatory knowledge, where technicalities as explored by
Riles (2011) become the key to ordering and socio-legal processes). Access to a
particular drug is contingent not only on the incorporation of patients in particular
medical regimes (as explored by Ecks 2008 in the case of providing free access to
Glivec), but also on the emplacement of drugs in particular systems of regulatory
knowledge.
In sum, critiques have been voiced against a seemingly increased attention to
treatment, and pharmaceutical treatment in particular, through access to medicines
campaigns, to the detriment of prevention (Biehl 2007). At the same time, the shifts
in focus between “new substances” and “basic medication,” and between different
regulatory systems (including emerging ones that regulate donations and access
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programs), order in different ways the types of drugs that become mobilized, sec-
tions of industry that become (dis)empowered, and the position of different
localities (from laboratories to hospitals) that are understood as valid spaces to
produce better health.
Discussion
Internationally, shifts can be discerned in regard to understanding health as a com-
modity – one that can be secured primarily through access to drugs (as opposed to
other measures, including infrastructure). Such discourses focus particularly on the
plights of citizens in low-income states, where images of the deserving poor are
juxtaposed with descriptions of greedy Euro–American pharmaceutical ﬁrms.
TRIPS is criticized as a legal tool that has the potential to dismantle the machinery
which might best enable medicines to freely circulate, and efforts have been made
(e.g. the Doha Declaration) to limit this possibility. Other actors, however, critique
the choices made by the WHO, NGOs and nations in regard to which drugs are
deemed essential for citizens to access. What is foregrounded in these narratives
is the importance of medicines for some diseases over or relative to others. This
may take the form of concerns that key diseases are being neglected (e.g.
malaria) in general, or speciﬁcally in comparison to others (in particular, HIV/
AIDS). Even more voices can be heard from the pharmaceutical industry. They
speak of drugs as, again, being essential to health, and regard the saturation of
markets with generics as worrying since it might ultimately stall or halt the
engines of pharmaceuticalization (e.g. by reducing industry proﬁts, and hence
their capacity to innovate). Just like those actors and associations involved with
access to medicines campaigns, the pharmaceutical industry deems more, and
better, drugs to be the key to health. This notion is concretized in the list of essential
medicines maintained and regularly revised by the WHO, and is at once sustained
by and a contributor to global processes of pharmaceuticalization. We do not make
this observation in order to suggest that drugs should not play a (perhaps key) role
in public health. Rather, we aim to underscore the sometimes surprising alignments
of interests and sociotechnical imaginaries that are constitutive of and produced
through processes of de/pharmaceuticalization.
Dialogue and debate around drugs in low-income countries are thus marked by
actual and imagined processes of de/pharmaceuticalization; as a whole, the discur-
sive space within which nations, NGOs, and international agencies operate is
marked by ambivalence about the nature and (possible) effects of law, the
meaning of health, and the propriety of particular kinds of intervention. Legal pro-
cesses play out across a mixture of porous boundaries and rigid networks, in which
“local” situations can have major import for the instantiation of “global” regimes.
These barely contained complexities explode when we attend to particular case
studies. In narrating the speciﬁc features of the Djibouti drug market, we have sig-
naled the “excess” of power that patents can have, and the ways in which they
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inform perceptions of the materiality of the products to which they adhere (cf. Barry
2005). Patents in Europe and elsewhere grant certain drugs a monopoly in those
nations, which might translate into a kind of prestige or desirability elsewhere
when professionals “brought up” with those brands in the regulated zone move
to jurisdictions without IP law. This enables a de facto system of regulation
wherein patents have power even where they do not ofﬁcially exist, profoundly
shaping drug markets and limiting the extent to which public health in Africa
can become de/pharmaceuticalized. Thus, like Biehl (2007), we assert that
policy-makers and patients can be subject to the enchantment of particular kinds
of drugs; yet, in contrast to his ﬁndings, the appeal of particular chemical com-
pounds does not necessarily result from their perceived necessity or novelty, nor
is it constituted through new arrangements between citizens and the state. In
effect, pharmaceutical use in Djibouti or in Ghana following TRIPS looks remark-
ably like “business as usual” for pharmacists and those with whom they trade
(though, as we have indicated, some developments have occurred). This is
largely because the relationship between law and daily practices is messy, uncertain
and reciprocally constitutive.
The multifaceted nature of the empirical reality we have sought to capture
through this analysis encourages, we believe, further debate about the scope,
limits and potential of the notion of “pharmaceuticalization” as a lens through
which to visualize the social life of drugs. In our account, particular axes of
debate and action can be located that have been disciplined through characterizing
them as processes of de/pharmaceuticalization. Yet, we have clearly not produced a
straightforward narrative of a uniform increase (or decrease) in drug consumption.
Rather, we have analyzed the extent to which past, current, and future laws both
inscribe and enact particular visions of health and the means of ensuring it, and
how these in turn impact on what kinds of pharmaceuticals are used, where, and
for what reasons. Undoubtedly, “pharmaceuticalization” seems an important
concept with which to approach research on drugs and direct our analytical gaze
(and the existing literature in this area is innovative and insightful). Arguably
less desirable, however, would be research that aims solely to document a rise
(or fall) in pharmaceutical production and consumption – and which, in the
process, elides the contradictions and complexities that characterize and constitute
these patterns of use. It is precisely these that are necessary to attend to in order to
map the textured terrain within which drugs travel.8
Conclusion
The emphasis of pharmaceuticals within current health systems “raises vital ques-
tions about public health priorities and their ﬁnancing, and the role of equity in the
human right to health” (Petryna 2009, 45). Our synthesis of a range of empirical
and conceptual work on law, drug markets, and access to medicines campaigns
has enabled us to produce a narrative that elucidates some of the complexities
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that “the legal” introduces to understandings of pharmaceuticalization. In particu-
lar, our contribution is to show how international law is being used to shape these
processes, but that its deployment has sometimes contingent and limited effects –
and that these are in turn structured by older forms of law through their interactions
with drugs. Our essay has thus documented the importance of both law and legal
processes to scholarly engagements with pharmaceuticalization, while showing
too that “the legal” simultaneously channels pharmaceutical ﬂows in different
ways and that it cannot be readily assumed without attention to speciﬁc cases.
Our (admittedly selective) attention to the role of law and governance in processes
of pharmaceuticalization also enjoins some reﬂection on the term itself. We suggest
that this provides an important organizing framework for studies of the production,
circulation and use of drugs, but wish to ﬂag that (as with concepts such as med-
icalization and geneticization) analysts who restrict their gaze to an axis of de/phar-
maceuticalization potentially obscure the complexity of the biopolitical matrix
within which pharmaceuticals come to have a social life.
Notes
1. See Bell and Figert (2012), but also Williams, Gabe, and Martin (2012).
2. As Williams, Gabe, and Martin (2012) remind us, in spite of the relative novelty of the term
“pharmaceuticalization,” social scientiﬁc engagements with drugs have been evident in the
literature for at least 30 years.
3. Importantly, the pharmaceutical industry also provides expertise: “companies are producers not
only of pills but also knowledge about their safety and efﬁcacy, and their gifts to doctors of travel
to conferences and workshops provide access to the latest expertise” (Lakoff 2005, 140).
4. See also Abraham (2007) and references therein.
5. It is perhaps worth noting that some social scientists have argued that the costs of pharmaceutical
innovation are not as high as international manufacturers often claim (Light and Warburton
2011).
6. The formation of TRIPS is also an illustration of the complex ways in which so-called global
systems are constituted, and of the mobility of particular kinds of law.
7. A fuller account of the patent situation in Djibouti is presented in Cloatre (2013).
8. There is also a danger that the focus on pharmaceuticalization as a contemporary concern will
also mask the historical context of drug marketing and use; the pervasive place of the
pharmaceutical industry in medicine and society is nothing new (Greene and Podolsky 2009)
and hence the challenge for scholars is to more precisely locate which shifts represent new
and important breaks and which are intensiﬁcations of processes that have documented
antecedents.
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